Rationale for Considering Oral Idasanutlin as a Therapeutic Option for COVID-19 Patients

Coronavirus infections and immune responses

(2020) Geng Li et al.   JOURNAL OF MEDICAL VIROLOGY

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

(2020) Chaolin Huang et al.   LANCET

MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia

(2020) Pau Montesinos et al.   Future Oncology

COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-Chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males?

(2020) Donato Gemmati et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019‐nCoV)

(2020) Shengjie Dong et al.   JOURNAL OF MEDICAL VIROLOGY

MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)

(2019) Arushi Khurana et al.   OncoTargets and Therapy

Oral Idasanutlin in Patients with Polycythemia Vera

(2019) John Mascarenhas et al.   BLOOD

Small-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype

(2018) Christopher D. Wiley et al.   Scientific Reports

MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer

(2017) Veronica Tisato et al.   Journal of Hematology & Oncology

p53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PLprovia E3 ubiquitin ligase RCHY1

(2016) Yue Ma-Lauer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

p53 Degradation by a Coronavirus Papain-like Protease Suppresses Type I Interferon Signaling

(2014) Lin Yuan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

(2013) Qingjie Ding et al.   JOURNAL OF MEDICINAL CHEMISTRY

Genome guardian p53 and viral infections

(2012) Yoshitaka Sato et al.   REVIEWS IN MEDICAL VIROLOGY

Coronaviruses post-SARS: update on replication and pathogenesis

(2009) Stanley Perlman et al.   NATURE REVIEWS MICROBIOLOGY

Transcriptional role of p53 in interferon-mediated antiviral immunity

(2008) César Muñoz-Fontela et al.   JOURNAL OF EXPERIMENTAL MEDICINE